Evolus (EOLS) Share-based Compensation (2017 - 2026)
Evolus (EOLS) posted Share-based Compensation of $5.1 million for Q1 2026, up 132.9% on a QoQ basis from -$15.6 million in Q4 2025, and down 13.7% year-over-year from $5.9 million in Q1 2025.
Evolus (EOLS) Share-based Compensation (2017 - 2026) Analysis & Trends
Evolus' Share-based Compensation history runs 10 years deep, the most recent figure standing at $5.1 million for Q1 2026.
- Quarterly Share-based Compensation fell 13.7% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$812000.0 (down 195.64% YoY) and the FY2023 annual result came in at $1.5 million, changed N/A from the prior year.
- Share-based Compensation was $5.1 million for Q1 2026 at Evolus, up from -$15.6 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $5.9 million in Q1 2025 and bottomed at -$16.1 million in Q4 2024.
- A 5-year average of $412000.0 and a median of $4.3 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation plunged 339.82% — and 2023, when it jumped 177.4%.
- Evolus' Share-based Compensation stood at -$5.9 million in 2022, then tumbled by 78.26% to -$10.6 million in 2023, then plunged by 51.94% to -$16.1 million in 2024, then rose by 3.31% to -$15.6 million in 2025, then surged by 132.9% to $5.1 million in 2026.
- Business Quant data shows EOLS's Share-based Compensation at $5.1 million in Q1 2026, -$15.6 million in Q4 2025, and $5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | 5.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.12 Mn |
| Mar 31, 2026 | 5.12 Mn |
| Dec 31, 2025 | -15.55 Mn |
| Dec 31, 2025 | -15.55 Mn |
| Sep 30, 2025 | 5.14 Mn |
| Sep 30, 2025 | 5.14 Mn |
| Jun 30, 2025 | 4.49 Mn |
| Jun 30, 2025 | 4.49 Mn |
| Mar 31, 2025 | 5.93 Mn |
| Mar 31, 2025 | 5.93 Mn |
| Dec 31, 2024 | -16.08 Mn |
| Dec 31, 2024 | -16.08 Mn |
| Sep 30, 2024 | 5.22 Mn |
| Sep 30, 2024 | 5.22 Mn |
| Jun 30, 2024 | 5.78 Mn |
| Jun 30, 2024 | 5.78 Mn |
| Mar 31, 2024 | 5.08 Mn |
| Mar 31, 2024 | 5.08 Mn |
| Dec 31, 2023 | -10.59 Mn |
| Dec 31, 2023 | -10.59 Mn |